CD4 T cells and toxicity from immune checkpoint blockade.

Area of Science:

• Immunology
• Oncology
• Computational Biology

Background:

• Immune checkpoint inhibitors (ICIs) are crucial cancer therapies but can cause severe immune-related adverse events (irAEs).
• Predicting and preventing irAEs is essential to optimize ICI therapy benefits and safety.
• Understanding the factors contributing to severe irAEs is critical for patient management.

Purpose of the Study:

• To identify pretreatment predictors of severe immune-related adverse events (irAEs) in advanced melanoma patients treated with ICIs.
• To establish a foundation for data-driven insights into irAE development for improved clinical translation.

Main Methods:

• Utilized multi-omic single-cell and bulk sequencing techniques (mass cytometry, scRNA-seq, scVDJ-seq, bulk RNA-seq, bulk TCR-seq).
• Analyzed peripheral blood samples from 71 patients with advanced melanoma across three cohorts.
• Correlated baseline immune cell populations and T-cell receptor (TCR) repertoire features with severe irAE development.

Main Results:

• Identified elevated activated CD4 effector memory T-cell abundance as a predictor of severe irAEs.
• Found increased TCR diversity in circulation to be associated with severe irAE development.
• These associations were independent of the specific organ system affected and observed within three months of ICI initiation.

Conclusions:

• Baseline circulating activated CD4 effector memory T-cells and TCR diversity are significant predictors of severe irAEs following ICI treatment.
• These findings offer potential for improved prediction and prevention strategies for irAEs.
• This research contributes to reducing morbidity and mortality associated with ICI therapy.